We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
-7%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
-$528M
(-16%)
Cap. Flow
-$782M
Cap. Flow
% of AUM
-27.48%
Top 10 Holdings %
Top 10 Hldgs %
40.1%
Holding
81
New
10
Increased
17
Reduced
14
Closed
17
Avg Time Held
4.2
quarters
Top 10 Avg Time Held
2.6
quarters
Top 20 Avg Time Held
3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$67.5M |
| 2 |
argenx
ARGX
|
+$50.5M |
| 3 |
Nuvalent
NUVL
|
+$46.9M |
| 4 |
Glaukos
GKOS
|
+$44.8M |
| 5 |
Blueprint Medicines
BPMC
|
+$42.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Guardant Health
GH
|
+$65.6M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$43.2M |
| 3 |
Paragon 28, Inc.
FNA
|
+$39.6M |
| 4 |
BioNTech
BNTX
|
+$35.3M |
| 5 |
Repligen
RGEN
|
+$31.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.44% |
| 2 | Miscellaneous | 32.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Viking Therapeutics
VKTX
$3.27B
| $34.7M | 1.22% |
1,435,955
-43,711
| -3% | -$1.38M |
2024 Q1
4 quarters
|
|
27
Penumbra
PEN
$12.6B
| $29.4M | 1.04% |
110,128
-73,700
| -40% | -$19.9M |
2022 Q4
9 quarters
|
|
28
Bicara Therapeutics
BCAX
$1.15B
| $28.2M | 0.99% |
2,162,803
+162,144
| +8% | +$2.15M |
2024 Q3
2 quarters
|
|
29
DELISTED
Day One Biopharmaceuticals
DAWN
| $28M | 0.99% |
3,536,853
-1,337,000
| -27% | -$14.4M |
2022 Q4
9 quarters
|
|
30
OrthoPediatrics
KIDS
$570M
| $27.3M | 0.96% |
1,107,770
| – | – |
2022 Q4
9 quarters
|
|
31
Harrow
HROW
$1.03B
| $25.5M | 0.89% |
956,839
+49,800
| +5% | +$1.49M |
2023 Q1
8 quarters
|
|
32
Maravai LifeSciences
MRVI
$970M
| $18.5M | 0.65% |
8,353,287
| – | – |
2023 Q2
7 quarters
|
|
33
Xencor
XNCR
$1.79B
| $17.6M | 0.62% |
1,655,690
+1,040,159
| +169% | +$17.2M |
2024 Q3
2 quarters
|
|
34
Ascendis Pharma A/S
ASND
$14.8B
| $16.6M | 0.58% |
+106,713
| New | +$15.2M |
2025 Q1
0 quarters
|
|
35
Oruka Therapeutics
ORKA
$5.04B
| $16.1M | 0.57% |
1,572,426
+424,750
| +37% | +$5.3M |
2024 Q3
2 quarters
|
|
36
Madrigal Pharmaceuticals
MDGL
$10.5B
| $16.1M | 0.57% |
+48,690
| New | +$16M |
2025 Q1
0 quarters
|
|
37
Sarepta Therapeutics
SRPT
$1.76B
| $15M | 0.53% |
234,500
-130,400
| -36% | -$13.7M |
2024 Q2
3 quarters
|
|
38
Replimune Group
REPL
$1.1B
| $14.3M | 0.5% |
1,461,826
-15,276
| -1% | -$189K |
2024 Q2
3 quarters
|
|
|
39
Repligen
RGEN
$11.4B
| $10.4M | 0.37% |
81,656
-202,167
| -71% | -$31.1M |
2023 Q2
7 quarters
|
|
40
Ironwood Pharmaceuticals
IRWD
$595M
| $9.74M | 0.34% |
6,622,584
+1,182,307
| +22% | +$2.82M |
2024 Q1
4 quarters
|
|
41
Celcuity
CELC
$2.9B
| $8.94M | 0.31% |
884,306
| – | – |
2024 Q2
3 quarters
|
|
42
Cullinan Oncology
CGEM
$873M
| $7.42M | 0.26% |
980,773
-195,400
| -17% | -$1.87M |
2023 Q2
7 quarters
|
|
43
Castle Biosciences
CSTL
$1.02B
| $7.31M | 0.26% |
+365,247
| New | +$9.04M |
2025 Q1
0 quarters
|
|
44
Dianthus Therapeutics
DNTH
$4.21B
| $6.81M | 0.24% |
375,355
-831,234
| -69% | -$18.3M |
2024 Q2
3 quarters
|
|
45
Pulmonx
LUNG
$76M
| $5.06M | 0.18% |
752,541
| – | – |
2022 Q4
9 quarters
|
|
|
MTSR
46
DELISTED
Metsera Inc
MTSR
| $4.76M | 0.17% |
+175,000
| New | +$4.96M |
2025 Q1
0 quarters
|
|
47
Aardvark Therapeutics
AARD
$85.4M
| $3.75M | 0.13% |
+500,000
| New | +$5.61M |
2025 Q1
0 quarters
|
|
48
Jade Biosciences
JBIO
$843M
| $3.62M | 0.13% |
41,157
| – | – |
2024 Q4
1 quarter
|
|
49
Zura Bio
ZURA
$420M
| $3.19M | 0.11% |
2,472,806
| – | – |
2024 Q3
2 quarters
|
|
50
Beta Bionics
BBNX
$906M
| $1.71M | 0.06% |
+140,000
| New | +$2.61M |
2025 Q1
0 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q1 2025 Portfolio in Review
As of Q1 2025, Braidwell held 81 positions worth $2.84B, down 16% from $3.37B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Braidwell withdrew a net $782M in Q1 2025, closing 17 positions and reducing 14 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $43.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 66% a quarter earlier, followed by Miscellaneous.
Against the trend, Braidwell opened a new position in Danaher worth $63.4M.
- Braidwell's largest Q1 2025 buy was Danaher: 309,339 shares worth $63.4M.
- Braidwell added most to argenx in Q1 2025, an estimated $50.5M increase.
- Braidwell's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $65.6M.
- Braidwell fully exited Avadel Pharmaceuticals in Q1 2025, selling an estimated $43.2M.
- Braidwell's ten largest holdings make up 40% of its $2.84B portfolio in Q1 2025.
- Braidwell opened 10 new positions and closed 17 in Q1 2025.
- Braidwell's portfolio value fell 16% quarter-over-quarter to $2.84B.
Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.